On February 28, 2023 Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, reported that management will present at the following upcoming investor conferences in March (Press release, Immunocore, FEB 28, 2023, View Source [SID1234627843])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cowen 43rd Annual Health Care Conference
Fireside Chat: Monday, March 6, 2023, at 1:30 p.m. ET
Oppenheimer 33rd Annual Healthcare Conference
Presentation: Tuesday, March 14, 2023, at 8:00 a.m. ET
Barclays Global Healthcare Conference
Fireside Chat: Wednesday, March 15, 2023, at 3:35 p.m. ET
Jefferies Biotech on the Bay Summit
1×1 and small group meetings: Thursday, March 16, 2023
The presentations will be webcast live and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentations will be made available for a limited time.